Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • SMS Pharma updates...

    SMS Pharma updates against USFDA statement on Ranitidine

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-13T14:31:35+05:30  |  Updated On 13 April 2020 2:31 PM IST
    SMS Pharma updates against USFDA statement on Ranitidine

    India: Through a recent release with the exchanges, SMS Pharma has provided update against USFDA statement on Ranitidine
    SMS Pharma is one of the manufacturers of Ranitidine HCl Active Pharmaceuticals Ingredient (API). In September 2019, The USFDA has observed that some ranitidine medicines contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels.

    The US Food and Drug Administration (USFDA or the Agency) has to request Ranitidine formulation manufacturers to withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step taken by the FDA in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications. FDA also made a statement as "We didn't observe unacceptable levels of NDMA in many of the samples that we tested. However, since we don't know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients unless its quality can be assured".

    "As a Ranitidine HCl drug substance manufacturer, we have performed the detailed risk assessment study for the formation of NDMA impurity in the Ranitidine HCl drug substance. It is observed that the NDMA impurity is increasing in the storage of the drug substance. Also, we have identified the root cause of the same", Company stated

    "Based on the risk assessment study, we have modified the process of Ranitidine HCl drug substance to control the NDMA impurity during the storage and the modified process details have been submitted to the FDA. The modified process material is more stable and the NDMA impurity is well controlled in our modified process of the Ranitidine HCl drug substance", Company further stated

    FDA has also requested all the formulators of Ranitidine HCl to provide the stability data of the drug product at the elevated long term stability conditions to confirm the stability data of the drug product w.r.to NDMA content.

    "Some of our customers have initiated the FDA recommended stability studies", SMS Pharma said

    "We have already submitted the available stability of Ranitidine HCl drug substance to the USFDA authority recently (March 2020). As per the normal process of GMP guidelines, the USFDA has conducted CGMP inspection in our API manufacturing facility during January 2020 and subsequently, we have received the EIR report. The validation batches of the modified process have been already initiated for the required stability studies and the stability data shall be updated to the Authority as required. We anticipate this activity would take about 9 to 10 months period", Company added

    "We further inform you that, to date, we have not sold any Ranitidine API for the commercial distribution in the US. Whatever the quantities sold are for the purpose of drug product development and the product has not entered into commercials till date in the US Market", the company further added

    "In view of the above, our commercial supplies of the Ranitidine HCl drug substance to our customers for US market from us is currently delayed by 9-10 months and expected to start by the end the current calendar year. In the meantime we will utilize these capacities to other existing products, hence, no impact on our operations as well as revenues during the current financial year as well as future years", SMS Pharma further said

    The share of SMS Pharmaceuticals Ltd's revenue contributed from Ranitidine product during the last couple of year is below 1% of the total revenues.

    Read also: SMS Pharmaceuticals Gets EIR From USFDA For Kandivalasa Facility

    sms-pharmausfdaranitidine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok